Matthew Roden, Aktis Oncology CEO (MPM Capital)

Are ra­dio­phar­ma­ceu­ti­cals ready for the main­stream? No­var­tis, Bris­tol My­ers Squibb bet yes on MP­M's plat­form take

Bri­an Good­man, Patrick Baeuer­le and Todd Fo­ley weren’t ex­act­ly look­ing to start a ra­dio­phar­ma­ceu­ti­cals com­pa­ny.

Rather, the team at MPM Cap­i­tal — which had been known for its will­ing­ness to seed and in­cu­bate new ideas for bat­tling can­cer — was search­ing for tech­nolo­gies that could con­fer “CAR-T like ef­fi­ca­cy” in sol­id tu­mors. They went through an­ti­body-drug con­ju­gates, cell ther­a­pies and T cell en­gagers but very quick­ly got hooked on some­thing else: al­pha emit­ting par­ti­cles.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA